Supreme Court to Consider Whether (Isolated) Human Genes are Patentable

On November 30, 2012, the U.S. Supreme Court agreed to decide a case presenting the seemingly simple, but legally complex, question, “Are human genes patentable?” After Bilski v. Kappos, 130 S. Ct. 3218 (2010) and Mayo Collaborative Services v. Prometheus Laboratories Inc., 132 S. Ct. 1289 (2012), this grant of certiorari represents the third time in recent years that the Supreme Court will assess the scope of patentable subject matter under 35 U.S.C. § 101.

The patents at issue in the case, held by Myriad Genetics, Inc. (Myriad), pertain to technologies for assessing a woman’s risk of breast and ovarian cancers and making clinical decisions on prophylactic courses of action, based on the discovery that mutations in the human BRCA1 and BRCA2 genes are associated with a greater risk of these cancers. The patents include claims directed to isolated DNA for BRCA1 and BRCA2.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Bilski, Biotechnology, DNA, Human Genes, Myriad, Patents, SCOTUS

Published In: Civil Procedure Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Venable LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »